JP2020500502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500502A5 JP2020500502A5 JP2019514263A JP2019514263A JP2020500502A5 JP 2020500502 A5 JP2020500502 A5 JP 2020500502A5 JP 2019514263 A JP2019514263 A JP 2019514263A JP 2019514263 A JP2019514263 A JP 2019514263A JP 2020500502 A5 JP2020500502 A5 JP 2020500502A5
- Authority
- JP
- Japan
- Prior art keywords
- bap1
- protein
- cancer
- wild
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1615842.0A GB201615842D0 (en) | 2016-09-16 | 2016-09-16 | Cell death biomarker |
| GB1615842.0 | 2016-09-16 | ||
| PCT/GB2017/052733 WO2018051110A1 (en) | 2016-09-16 | 2017-09-15 | Cell death biomarker |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500502A JP2020500502A (ja) | 2020-01-16 |
| JP2020500502A5 true JP2020500502A5 (enExample) | 2020-11-05 |
| JP7211936B2 JP7211936B2 (ja) | 2023-01-24 |
Family
ID=57288813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514263A Active JP7211936B2 (ja) | 2016-09-16 | 2017-09-15 | 細胞死のバイオマーカー |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11789012B2 (enExample) |
| EP (1) | EP3513192B1 (enExample) |
| JP (1) | JP7211936B2 (enExample) |
| AU (1) | AU2017327994B2 (enExample) |
| DK (1) | DK3513192T3 (enExample) |
| ES (1) | ES2863274T3 (enExample) |
| GB (1) | GB201615842D0 (enExample) |
| WO (1) | WO2018051110A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CN112961864A (zh) * | 2021-02-26 | 2021-06-15 | 广州市妇女儿童医疗中心 | 突变的asxl3基因及应用 |
| CN114478797B (zh) * | 2021-11-24 | 2023-10-27 | 中山大学附属第五医院 | 一种靶向ddx24蛋白的水解靶向嵌合体及其应用 |
| US12456104B2 (en) | 2023-02-10 | 2025-10-28 | linch Limited | Dynamic multi-path transfers |
| CN117843657B (zh) * | 2023-12-30 | 2025-08-05 | 新乡医学院 | Brd4/nampt双靶向抑制剂及其作为抗肝癌药物的应用 |
| US12608709B2 (en) | 2024-03-15 | 2026-04-21 | Degensoft Ltd. | Decentralized systems and methods for response generation to API calls |
| WO2025219949A1 (en) | 2024-04-18 | 2025-10-23 | 1Inch Limited | Secure cross-chain atomic swaps |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20020169123A1 (en) * | 2001-02-27 | 2002-11-14 | The Trustees Of The University Of Pennsylvania | Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells |
| EP2044434B1 (en) | 2006-06-20 | 2015-11-18 | Genentech, Inc. | Methods and materials for observing apoptosis by detecting fragments of clathrin-pathway components |
| WO2012040614A1 (en) * | 2010-09-23 | 2012-03-29 | The Washington University | Compositions and methods for detecting cancer metastasis |
| AU2012364924A1 (en) | 2011-02-16 | 2013-09-12 | Medical University Of Graz | BAP1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia |
| JP6108571B2 (ja) | 2013-03-28 | 2017-04-05 | 国立大学法人東北大学 | 食道癌の発症リスクを判定する方法及びキット |
| CA2927023C (en) | 2013-10-10 | 2022-08-02 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| US20160101071A1 (en) * | 2014-04-28 | 2016-04-14 | Wisconsin Alumni Research Foundation | Combination cancer treatment |
| CA2948883A1 (en) | 2014-06-02 | 2015-12-10 | Pharmakea, Inc. | Deubiquitinase inhibitors |
| CA2952285A1 (en) | 2014-06-19 | 2015-12-23 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to ezh2 inhibitors |
-
2016
- 2016-09-16 GB GBGB1615842.0A patent/GB201615842D0/en not_active Ceased
-
2017
- 2017-09-15 US US16/333,590 patent/US11789012B2/en active Active
- 2017-09-15 ES ES17771553T patent/ES2863274T3/es active Active
- 2017-09-15 DK DK17771553.9T patent/DK3513192T3/da active
- 2017-09-15 EP EP17771553.9A patent/EP3513192B1/en active Active
- 2017-09-15 JP JP2019514263A patent/JP7211936B2/ja active Active
- 2017-09-15 AU AU2017327994A patent/AU2017327994B2/en active Active
- 2017-09-15 WO PCT/GB2017/052733 patent/WO2018051110A1/en not_active Ceased
-
2023
- 2023-04-12 US US18/299,415 patent/US20240118266A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation | |
| Zhou et al. | MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1 | |
| ES2562077T3 (es) | Regiones ultraconservadas que codifican ARNnc | |
| Yuan et al. | Advances in poly (rC)-binding protein 2: Structure, molecular function, and roles in cancer | |
| Okayama et al. | NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression | |
| Gomez et al. | Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks | |
| Dai et al. | Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma | |
| Preukschas et al. | Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies | |
| JP7406278B2 (ja) | 腫瘍マーカー及び治療ターゲットとしての長鎖ノンコーディングｒｎａ ｌｅｔｎ | |
| Zhao et al. | Targeted inhibition of MCT4 disrupts intracellular pH homeostasis and confers self-regulated apoptosis on hepatocellular carcinoma | |
| Xu et al. | Hsa_circ_0001869 promotes NSCLC progression via sponging miR-638 and enhancing FOSL2 expression | |
| CN103842508A (zh) | 白蛋白产生和细胞增殖 | |
| JP2017518764A (ja) | 癌の処置のための多標的指向ＲＮＡｉ | |
| KR20170107958A (ko) | 트랜스페린 수용체 (TfR)에 대한 RNA 압타머 | |
| JP7211936B2 (ja) | 細胞死のバイオマーカー | |
| JP6543612B2 (ja) | 大腸癌の治療剤、及び大腸癌患者の予後の予測方法 | |
| JP2017006137A (ja) | 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法 | |
| WO2009075787A1 (en) | Compositions and methods of treating neoplasia | |
| Liu et al. | Ciz1 promotes tumorigenicity of prostate carcinoma cells | |
| Li et al. | RETRACTED ARTICLE: LOXL1-AS1 Drives The Progression Of Gastric Cancer Via Regulating miR-142-5p/PIK3CA Axis | |
| Zhang et al. | Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo | |
| US12024707B2 (en) | Methods and compositions for modulating lncRNAs and methods of treatment based on lncRNA expression | |
| Guo et al. | Downregulation of TNFRSF19 and RAB43 by a novel miRNA, miR-HCC3, promotes proliferation and epithelial–mesenchymal transition in hepatocellular carcinoma cells | |
| ES2890556T3 (es) | Combinación de inhibidor de EGFR e inhibidor de MEK para su uso en el tratamiento del cáncer con mutación de NRAS | |
| WO2013047941A1 (ko) | 비소세포성 폐암에서 ｔｍ４ｓｆ４의 발현 또는 활성의 조절을 통한 방사선 저항성 및 암세포의 성장, 전이, 및 침윤능력을 저하시키는 방법 |